Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

LY-293558. Eli Lilly & Co.

¹Departments of Anesthesiology and Pharmacology & Toxicology, Queen's University, Kingston General Hospital, Kingston, Ontario K7L 2V7, Canada. gilroni@post.queensu.ca

Current Opinion in Investigational Drugs (London, England : 2000)

|November 23, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association of peri-operative prescription of non-steroidal anti-inflammatory drugs with continued prescription of opioids after total knee arthroplasty: a retrospective claims-based cohort study.

Anaesthesia·2024

Same author

Adverse event assessment and reporting in trials of newer treatments for post-operative pain.

Acta anaesthesiologica Scandinavica·2016

Same author

Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society.

Pain research & management·2007

Same author

Corticosteroids in postoperative pain management: future research directions for a multifaceted therapy.

Acta anaesthesiologica Scandinavica·2004

Same author

The effects of intrathecal gabapentin on spinal morphine tolerance in the rat tail-flick and paw pressure tests.

Anesthesia and analgesia·2004

Same author

Hemispheric lateralization of somatosensory processing.

Journal of neurophysiology·2001

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Lilly is developing LY-215490, an AMPA antagonist, for conditions including stroke, ischemia, and epilepsy. This compound is also being investigated as a pain reliever, with LY-293558 in Phase II trials for pain by 2000.

Area of Science:

Neuroscience
Pharmacology

Background:

AMPA receptors play a crucial role in synaptic transmission and neuronal excitability.
Dysregulation of AMPA receptor activity is implicated in various neurological disorders.

Purpose of the Study:

To investigate the therapeutic potential of LY-215490, a selective and competitive AMPA antagonist.
To evaluate LY-215490 for treating cerebral infarction, cerebrovascular ischemia, and epilepsy.
To explore the analgesic properties of LY-215490 and its related compound LY-293558.

Main Methods:

Development of LY-215490, a racemic compound.
Preclinical and clinical investigations into the efficacy of LY-215490 and LY-293558.
Phase II clinical trials for LY-293558 in pain management.

Related Experiment Videos

Main Results:

LY-215490 demonstrates potential as a treatment for neurological conditions.
LY-215490 exhibits promise as an analgesic agent.
LY-293558 advanced to Phase II trials for pain, indicating positive early-stage results.

Conclusions:

Selective AMPA antagonists like LY-215490 represent a promising therapeutic strategy.
Further research and clinical development are warranted for LY-215490 and related compounds in neurological and pain disorders.